Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Rare Kidney Diseases Market Set To Climb From $3.31 Billion In 2026 To $4.88 Billion By 2030
The rare kidney diseases market size has seen robust growth over recent years. It is forecast to grow from $3.03 billion in 2025 to $3.32 billion in 2026, at a compound annual growth rate (CAGR) of 9.5%. The expansion witnessed in the past can be ascribed to several factors, including the scarcity of treatment options for rare renal disorders, increasing understanding of genetic kidney diseases, a rise in the prevalence of autoimmune-related nephropathies, the establishment of more nephrology specialty care centers, and the early adoption of immunosuppressive therapies.
The rare kidney diseases market is anticipated to experience substantial growth over the next few years. It is projected to expand to $4.88 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This market’s expansion during the forecast period can be attributed to advancements in genomics-based drug discovery, an increase in orphan drug approvals, greater investment in rare disease research, the growing application of personalized medicine strategies, and an expanding pipeline of complement and immune-targeted therapies. Noteworthy trends for the same period include a heightened focus on targeted therapies for rare renal disorders, increased clinical trial activity for orphan kidney drugs, the rising adoption of biologics in immune-mediated kidney diseases, the spread of companion diagnostics for early disease detection, and more regulatory incentives for rare disease drug development.
Get A Free Sample Report With In-Depth Market Insights:
Rare Kidney Diseases Market Demand Drivers: What’s Powering Industry Growth?
The rising occurrence of chronic kidney disease (CKD) significantly contributes to the rare kidney disease market. CKD is defined as a disorder where kidneys are damaged and cannot properly filter blood. This increased prevalence of chronic kidney diseases heightens the chances of patients developing rare kidney diseases, subsequently boosting the demand for therapeutics for these conditions. For example, in August 2025, the National Kidney Foundation, Inc., a U.S.-based voluntary nonprofit health organization, reported that the Senate approved a $5 million increase in the FY 2026 Labor, Health and Human Services, and Education appropriations bill to support kidney transplant reform and early detection efforts. This funding increase brings the total for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Thus, the growing prevalence of chronic kidney disease (CKD) will drive the rare kidney disease market.
Rare Kidney Diseases Market Segment Performance And Emerging Opportunities
The rare kidney diseases market covered in this report is segmented –
1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type Of Molecule: Small Molecules, Biologics
3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration
Subsegments:
1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management
2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders
Rare Kidney Diseases Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies within the rare kidney diseases market are primarily directing their efforts towards the development of non-immunosuppressive therapies for managing these conditions. This distinctive non-immunosuppressive treatment offers a unique approach for patients afflicted with progressive kidney diseases, a feat not achievable by conventional therapies currently utilized for rare kidney diseases. As an illustration, in February 2023, Travere Therapeutics, a biopharmaceutical firm based in the US, unveiled sparsentan, commercially known as Filspari. This medication stands as the inaugural non-immunosuppressive therapy granted approval for primary immunoglobulin A nephropathy (IgAN). Filspari operates with a unique mode of action by obstructing angiotensin and endothelin receptors. This particular characteristic differentiates Filspari from angiotensin-targeting ACE inhibitors and ARBs, which are familiar medications primarily prescribed for hypertension but have been repurposed for IgAN treatment due to their capacity to reduce blood pressure within the kidney.
Rare Kidney Diseases Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.
View The Full Rare Kidney Diseases Market Report:
Rare Kidney Diseases Market Regional Distribution: Which Areas Power Market Growth?
North America was the leading region in the rare kidney disease market in 2025. The regions covered in the rare kidney diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
